Tumor Necrosis Factor Inactivation in the Management of Rheumatoid Arthritis

Southern Medical Journal

Volumn 93, Issue 8, 2000, Pages 753-759

  Baumgartner, Scott W ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Physician's Clinic of Spokane   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

DRUG EFFECT; HUMAN; IMMUNOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034241869     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200008000-00002     Document Type: Article

References (52)

1. Fuchs HA, Sergent JS: Rheumatoid arthritis: the clinical picture. Arthritis and Allied Conditions: A Textbook of Rheumatology. Koopman WJ (ed). Baltimore, Williams & Wilkins, 13th Ed, 1997, pp 1041-1070
2. Albani S, Carson DA: Etiology and pathogenesis of rheumatoid arthritis. Arthritis and Allied Conditions: A Textbook of Rheumatology. Koopman WJ (ed). Baltimore, Williams & Wilkins. 13th Ed, 1997, pp 979-992
3. Miossec P, Chomarat P, Dechanet J: Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996; 17:170-173
4. De Keyser F, Elewaut D, Vermeersch J, et al: The role of T cells in rheumatoid arthritis. Clin Rheumatol 1995; 14(suppl 2):5-9
5. Arend WP: The pathophysiology and treatment of rheumatoid arthritis (Editorial). Arthritis Rheum 1997; 40:595-597
6. Feldmann M: The cytokine network in rheumatoid arthritis: definition of TNFα as a therapeutic target. J R Coll Physicians Lond 1996; 30:560-570
7. Brennan FM, Chantry D, Jackson A, et al: Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2:244-247
8. Butler DM, Maini RN, Feldmann M, et al: Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6:225-230
9. Haworth C, Brennan FM, Chantry D, et al: Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 1991; 21:2575-2579
10. Eigler A, Sinha B, Hartmann G, et al: Taming TNF: strategies to restrain this proinflaminatory cytokine. Immunol Today 1997; 18:487-492
11. Husby G, Williams RC Jr: Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1:363-371
12. Saxne T, Palladino MA Jr, Heinegård D, et al: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31:1041-1045
13. Chu CQ, Field M, Feldmann M, et al: Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1125-1132
14. Allard SA, Muirden KD, Camplejohn KL, et al: Chondrocyle-derived cells and matrix at the rheumatoid cartilage-pannus junction identified with monoclonal antibodies. Rheumatol Int 1987; 7:153-159
15. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162:2163-2168
16. Saklatvala J: Tumour necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage (Letter). Nature 1986; 322:547-549
17. Bertolini DR, Nedwin GE, Bringman TS, et al: Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319:516-518
18. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89:9784-9788
19. Wooley PH, Dutcher J, Widmer MB, et al: Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151:6602-6607
20. Cooper WO, Fava RA, Gates CA, et al: Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin Exp Immunol 1992; 89:244-250
21. Keffer J, Probert L, Cazlaris H, et al: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031
22. Cope AP, Aderka D, Doherty M, et al: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35:1160-1169
23. Van Zee KJ, Kohno T, Fischer E, et al: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-4849
24. Roux-Lombard P, Punzi L, Hasler F, et al: Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36:485-489
25. Steiner G, Studnicka-Benke A, Witzmann G, et al: Soluble-receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995; 22:406-412
26. Moreland LW, Heck LW Jr, Koopman WJ: Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40:397-409
27. Arend WP, Malyak M, Guthridge CJ, et al: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55
28. Franklin CM: Clinical experience with soluble TNF p75 receptor in RA. Semin Arthritis Rheum 1999; 29:1-12
29. Goldenberg MM: Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999; 21:75-87
30. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151:1548-1561
31. Moreland LW, Baumgartner SW, Schiff MH, et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141-147
32. Felson DT, Andersen JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-735
33. Fries JF, Spitz PW, Young DY: The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789-793
34. Moreland LW, Baumgartner SW, Tindall EA, et al: Longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc; ENBREL) (Abstract). Biomedicine '98: Medical Research from Bench to Bedside, Washington, DC, May 1-3, 1998
35. Baumgartner SW, Moreland LW, Schiff M, et al: Phase III and longterm treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR:Fc) (Abstract). Rheumatology in Europe 10th Symposium EULAR, Vienna, Austria, Nov 19-22, 1997
36. Moreland LW, Schiff MH, Baumgartner SW, et al: Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1999; 130:478-486
37. Weinblatt ME, Kremer JM, Bankhurst AD, et al: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259
38. Elliott MJ, Maini RN, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344:1105-1110
39. Rankin ECC, Choy EHS, Kassimos D, et al: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34:334-342
40. Elliott MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36:1681-1690
41. Elliott MJ, Maini RN, Feldmann M, et al: Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344:1125-1127
42. Maini RN, Breedveld FC, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-1563
43. Lipsky P, St. Clair W, Furst D, et al: 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade) in patients with active RA despite methotrexate (Abstract). Arthritis Rheum 1999; 42(suppl 9):S401
44. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-2204
45. Eberhardt KB, Fex E: Functional impairment and disability in early rheumatoid arthritis - development over 5 years. J Rheumatol 1995; 22:1037-1042
46. Finck B, Martin R, Fleischmann R, et al: A phase III trial of etanercept vs methotroxate (MTX) in early rheumatoid arthritis (Enbrel ERA trial) (Abstract). Arthritis Rheum 1999; 42(suppl 9):S117
47. Rau R, Herborn G, Sander O, et al: Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis (Abstract). Arthritis Rheum 1999; 42(suppl 9):S400
48. Moreland LW, Bucy R, Weinblatt ME, et al: Effects of TNF receptor (p75) fusion protein (TNFR:Fc; Enbrel) on immune function (Abstract). Arthritis Rheum 1998; 41(suppl 9):S59
49. ENBREL (manufacturer's prescribing information). Seattle, Immunex Corp, 1999
50. Moreland LW, Baumgartner SW, Tindall EA, et al: Long-term safety and efficacy of etanercept (Enbrel) in DMARD refractory rheumatoid arthritis (RA) (Abstract). Rheumatology in Europe 12th Symposium EULAR, Glasgow, Scotland, June 6-12, 1999
51. Wilske KR: Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience. Semin Arthritis Rheum 1993; 23:11-18
52. van der Heide A, Jacobs JWG, Bijlsma JWJ, et al: The effectiveness of early treatment with "second-line" antirheumatic drugs, a randomized, controlled trial. Ann Intern Med 1996; 124:699-707